RCKT Q3 2023 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$65M

Net Income

-$62M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$62M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$599M

Total Liabilities

$58M

Stockholders' Equity

$541M

Cash & Equivalents

$226M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$65M	-$58M	-11.9%
Net Income	-$62M	-$58M	-7.2%